Azaftig, a proteoglycan for monitoring cachexia and for control of obesity
AssigneeBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College
InventorsChandan Prasad, Julio E. Figueroa, II, Parakat Vijayagopal
Life of this patent
Estimating the term…
Abstract
A proteoglycan (“azaftig”) with a molecular weight of approximately 24,000 Dalton has been isolated and partially characterized from the urine of cachectic cancer and non-cancer patients. Azaftig has been shown to bind to receptors on fat cell membranes, and to cause lipolysis. Azaftig does not bind to muscle cell membranes, or cause proteolysis in muscle tissue. Azaftig detection in urine or other body fluids will allow early identification of patients in which weight loss may become a problem. Azaftig may also aid fat loss in humans in which obesity is a threat to health.
Claims3
A substantially pure azaftig wherein said azaftig is a proteoglycan of molecular weight about 24 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;
- wherein said azaftig is obtained from or is identical to a proteoglycan obtained from urine of cachectic cancer patients;
- wherein said azaftig is a proteoglycan as determined by partial digestion with either chondroitinase ABC or chondroitinase AC;
- wherein said azaftig is not readily digested by neuraminidase;
- wherein said azaftig binds to fat cell membranes;
- wherein said azaftig does not bind to muscle cell membranes;
- and wherein said azaftig is a negatively charged molecule as determined by DEAE-Sephacel chromatography at pH 7.0.
A method for inducing weight loss in a mammal, comprising administering an effective amount of azaftig to the mammal;
- wherein azaftig is a proteoglycan of molecular weight about 24 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;
- wherein azaftig is obtained from or is identical to a proteoglycan obtained from urine of cachectic cancer patients;
- wherein azaftig is a proteoglycan as determined by partial digestion with either chondroitinase ABC or chondroitinase AC;
- wherein azaftig is not readily digested by neuraminidase;
- wherein said azaftig binds to fat cell membranes;
- wherein azaftig does not bind to muscle cell membranes;
- and wherein azaftig is a negatively charged molecule as determined by DEAE-Sephacel chromatography at pH 7.0.
Dependencies are inferred from the claim text.